Skip to main content
. 2022 Mar 23;109(1):50–57. doi: 10.1111/ejh.13768

FIGURE 2.

FIGURE 2

Time to AML transformation in three distinct molecularly defined CMML cohorts including TET2 monomutated patients (T, n = 10), TET2/SRSF2 bimutated patients (TS, n = 19), and patients who had NRAS mutations in addition to TET2/SRSF2 comutations (TSN, n = 14)